Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Avesta's approach involves working with patients' mental health providers to tailor treatments to individual needs.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

My practice is integrated care for adults (psychiatric medication management, psychedelic esketamine (Spravato) treatments, primary care, weight loss injection therapy and asthetics). I am board ...